Illumina are a global leader in genomics – an industry at the intersection of biology and technology.
|Address:||Chesterford Research Park, Little Chesterford, Nr Saffron Walden|
|Membership type:||Corporate 51+ (£1,000+VAT pa)|
At the most fundamental level, we enable our customers to read and understand genetic variations. We strive to make our solutions increasingly simple, more accessible, and always reliable. As a result, discoveries that were unimaginable even a few years ago are now becoming routine – and are making their way into patient treatment.
Headquartered in San Diego, California, Illumina (NASDAQ: ILMN), is a leading developer, manufacturer, and marketer of next generation life science tools and integrated systems for large-scale analysis of genetic variation and biological function. These systems are enabling studies that were not even imaginable just a few years ago, and moving us closer to the realization of personalized medicine. With the innovative advances in our sequencing technologies, we are rapidly impacting the clinical market in areas such as reproductive health and oncology. The expanding Illumina oncology portfolio of next- generation sequencing NGS and microarray technologies is revolutionizing cancer genomics research. Our customers include a broad range of academic, government, pharmaceutical, biotechnology, and other leading institutions around the globe.
lllumina has experienced phenomenal growth from $10 million in revenues in 2002 to over $1.4 billion in 2013. Forbes named Illumina #1 on the 2009 list of 25 Fastest-Growing Technology Companies in the United States, the second time over a three year period that Forbes ranked Illumina #1 on its list of rapidly growing technology companies. Illumina was also named #1 smartest company in the world as part of MIT’s 2014 Technology Review. As of August 2014, the company had a $24 billion market capitalization.
Illumina, Inc. has announced estimated first quarter revenue of approximately $572 million, a 6% increase compared to $539 million in the first quarter of 2015 and 7% growth on a constant currency basis. This estimate, which is unaudited, is based on management's preliminary financial analysis.
19 April 2016Read in full
Illumina, Inc has announced GRAIL, a new company formed to enable cancer screening from a simple blood test. Powered by Illumina sequencing technology, GRAIL will develop a pan-cancer screening test by directly measuring circulating nucleic acids in blood.
11 January 2016Read in full
Life Sciences Minister George Freeman MP attended BioMed Realty’s groundbreaking ceremony of the new 155,000 square foot pre-let laboratory building for Illumina at Granta Park, Cambridge, yesterday (Weds).
22 October 2015Read in full
(BUSINESS WIRE)--Illumina, Inc. announced it has signed a definitive agreement to acquire GenoLogics Life Sciences Software, a developer of industry-leading laboratory information management systems (LIMS) for life sciences organisations.
5 August 2015Read in full
Annoroad and Illumina, Inc. today announced they have entered into an agreement to jointly develop advanced clinical applications for reproductive health based on next-generation sequencing (NGS) technology. The collaboration signals the increasing importance of genomic applications to improve healthcare in China.
10 June 2015Read in full
Cloud Health will promote the application of genetic sequencing technologies for both public health and clinical research within China, using the most powerful whole-genome sequencing platform in the world.
23 April 2015Read in full
Berry Genomics NextSeq CN500 instrument and non-invasive prenatal testing reagent kit receives Chinese FDA premarket clearance.
1 April 2015Read in full